Novartis Bets Up to $7.8 Billion on an mRNA Drug That Turns the Body Into Its Own Antibody Factory

Novartis has signed a licensing deal worth up to $7.8 billion with China’s Abogen Biosciences for an experimental autoimmune treatment built on mRNA. Novartis will pay $575 million upfront, with up to roughly $7.2 billion more in milestones, for global rights to ABO2203, plus an exclusive option on further drugs from Abogen’s RNA platform. The agreement was announced on October 2, 2026.

What ABO2203 is

ABO2203 combines two ideas. The first is a T-cell engager: a two-armed antibody-like protein that grabs a T cell with one arm (via CD3) and a B cell with the other (via CD19), bringing them together so the T cell destroys the B cell. The second is mRNA delivery. Rather than manufacturing that protein in a factory and infusing it, ABO2203 is an injection of mRNA wrapped in lipid nanoparticles — the same basic technology as mRNA Covid vaccines — that instructs the patient’s own cells to produce the T-cell engager for a period of time.

Why target B cells in autoimmune disease

In conditions such as lupus, myasthenia gravis and immune thrombocytopenia, B cells produce antibodies that attack the body’s own tissues. Existing drugs such as rituximab deplete B cells but often incompletely, especially deep in tissues. Over the past few years, CAR-T therapy — engineered T cells originally developed for blood cancers — showed that wiping out B cells very thoroughly can put severe autoimmune disease into lasting, drug-free remission, an effect often called an “immune reset.” The challenge has been how to deliver that reset more simply and safely.

The appeal of an “in vivo” approach

CAR-T is complicated: a patient’s cells are collected, engineered in a specialized facility over weeks, and re-infused after chemotherapy, at a cost of hundreds of thousands of dollars. Protein T-cell engagers are simpler but usually need repeated or continuous dosing. An mRNA that makes the engager inside the body could, in principle, offer the depth of B-cell depletion with an off-the-shelf injection, no cell manufacturing and no chemotherapy. Because mRNA is short-lived, the effect is also temporary and adjustable, which may be a safety advantage.

The early data

The evidence so far is thin. Abogen has reported that ABO2203 depleted B cells in three patients with immune thrombocytopenia, a bleeding disorder caused by antibodies against platelets, without causing cytokine release syndrome, the dangerous inflammatory reaction that can follow T-cell-activating therapies. Three patients cannot establish how well or how safely the drug works; that will take much larger trials across several diseases. Immune thrombocytopenia is a sensible first test because platelet counts give a quick, objective read on whether removing B cells is helping; the bigger commercial prizes are conditions such as lupus, where current treatments leave many patients with ongoing disease and long-term steroid use.

Why Novartis, and why now

Novartis has been one of the most aggressive companies pursuing immune reset, with its own CAR-T program for autoimmune disease. According to Fierce Biotech, the deal comes weeks after Novartis paused an autoimmune CAR-T program following three patient deaths. That setback underlines the risk of intensive cell therapy in people who, unlike cancer patients, often have many years of life ahead with existing treatments — and it helps explain the appeal of a potentially gentler, more controllable way to reach the same goal.

The China factor

The deal is another example of Western drugmakers turning to Chinese biotechs for early-stage innovation. Abogen is best known for developing an mRNA Covid vaccine in China and has since expanded its RNA platform into therapeutics. Licensing from China has become one of the industry’s defining trends, offering large companies fast access to new candidates, and it is drawing growing scrutiny from US policymakers.

A crowded field

Novartis is not alone. Many companies are testing protein T-cell engagers originally developed for blood cancers in autoimmune disease, while others pursue in vivo CAR-T, which uses similar delivery technology to engineer T cells inside the body. Which approach wins will depend on depth and durability of response, safety, and convenience — and it is possible that different diseases will favor different tools.

The caveats

Beyond the tiny dataset, several questions are open. How long does B-cell depletion last, and how long does a remission persist once B cells return? How often would the injection need repeating? Does the lipid nanoparticle cause its own side effects with repeated dosing? And, as with all deals of this kind, most of the headline value is contingent: milestones are paid only if the drug succeeds in trials, wins approval and sells.

What it means

For patients, this is a long-range development, not a near-term option. But it shows where autoimmune treatment is heading: away from lifelong immune suppression and toward short, deep interventions that aim to reset the immune system. For a fuller picture of the technology that started this, see our explainer on CAR-T therapy. This is business news, not investment or medical advice.